

Highlights of This Issue 3809

SPECIAL FEATURES

CCR New Strategies

- 3811 **New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways**
Arvind Dasari and Wells A. Messersmith

CCR Translations

- 3819 **Killing the Killer: Natural Killer Cells to Treat Ewing's Sarcoma**
Yong-Oon Ahn, Brenda Weigel, and Michael R. Verneris
See article p. 3901
- 3822 **Fluorescence Resonance Energy Transfer Biosensors for Cancer Detection and Evaluation of Drug Efficacy**
Shaoying Lu and Yingxiao Wang
See article p. 3964

Molecular Pathways

- 3825 **Deregulated Intracellular Signaling by Mutated c-CBL in Myeloid Neoplasms**
Seishi Ogawa, Lee-Yung Shih, Takahiro Suzuki, Makoto Otsu, Hiromitsu Nakauchi, H. Phillip Koeffler, and Masashi Sanada

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

- 3832 **Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk**
Zhe-Yi Hu, Qi Yu, Qi Pei, and Cheng Guo

HUMAN CANCER BIOLOGY

- 3843 **Sperm DNA Integrity in Men Treated for Childhood Cancer**
Patrik Romerius, Olof Ståhl, Christian Moëll, Thomas Relander, Eva Cavallin-Ståhl, Helen Gustafsson, Kerstin Löfvander Thapper, Katarina Jepson, Marcello Spanò, Thomas Wiebe, Yvonne Lundberg Giwerzman, and Aleksander Giwerzman
- 3851 **GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas**
Patrick Roth, Markus Junker, Isabel Tritschler, Michel Mittelbronn, Yvonne Dombrowski, Samuel N. Breit, Ghazaleh Tabatabai, Wolfgang Wick, Michael Weller, and Jörg Wischhusen
- 3860 **Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma**
Toshima Z. Parris, Anna Danielsson, Szilárd Nemes, Anikó Kovács, Ulla Delle, Ghita Fallenius, Elin Möllerström, Per Karlsson, and Khalil Helou
- 3875 **CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis**
Gong Yang, Daniel G. Rosen, Guangzhi Liu, Fan Yang, Xiaoqing Guo, Xue Xiao, Fengxia Xue, Imelda Mercado-Uribe, Jiaoti Huang, Sue-Hwa Lin, Gordon B. Mills, and Jinsong Liu

CANCER THERAPY: PRECLINICAL

- 3887 **Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy**
Anil Bagri, Leanne Berry, Bert Gunter, Mallika Singh, Ian Kasman, Lisa A. Damico, Hong Xiang, Maike Schmidt, Germaine Fuh, Beth Hollister, Oliver Rosen, and Greg D. Plowman

- 3901 **Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors**
Duck Cho, David R. Shook, Noriko Shimasaki, Yu-Hsiang Chang, Hiroyuki Fujisaki, and Dario Campana
See commentary p. 3819
- 3910 **Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles**
Hee Dong Han, Lingegowda S. Mangala, Jeong Won Lee, Mian M.K. Shahzad, Hye Sun Kim, Deyu Shen, Eun Ji Nam, Edna M. Mora, Rebecca L. Stone, Chunhua Lu, Sun Joo Lee, Ju Won Roh, Alpa M. Nick, Gabriel Lopez-Berestein, and Anil K. Sood
- 3923 **The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy**
Yue Wei, Tapan Kadia, Weigang Tong, Ming Zhang, Yu Jia, Hui Yang, Yumin Hu, Francesco Paolo Tambaro, Jean Viallet, Susan O'Brien, and Guillermo Garcia-Manero
- 3933 **Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors**
Andrea Bertotti, Cecilia Bracco, Flavia Girolami, Davide Torti, Stefania Gastaldi, Francesco Galimi, Enzo Medico, Paul Elvin, Paolo M. Comoglio, and Livio Trusolino
- 3944 **Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine**
Claudio Pisano, Loredana Vesci, Ferdinando Maria Milazzo, Mario Berardino Guglielmi, Rosanna Foderà, Marcella Barbarino, Maurizio D'Incalci, Massimo Zuchetti, Giovanna Petrangolini, Monica Tortoreto, Paola Perego, Valentina Zuco, Augusto Orlandi, Daniela Passeri, Paolo Carminati, Claudio Cavazza, and Franco Zunino
- 3954 **Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer**
Maoyong Fu, Erin L. Maresh, Robert A. Soslow, Mohammad Alavi, Vei Mah, Qin Zhou, Alexia Iasonos, Lee Goodglick, Lynn K. Gordon, Jonathan Braun, and Madhuri Wadehra

IMAGING, DIAGNOSIS, PROGNOSIS

- 3964 **A Novel FRET-Based Biosensor for the Measurement of BCR-ABL Activity and Its Response to Drugs in Living Cells**
Tatsuaki Mizutani, Takeshi Kondo, Stephanie Darmanin, Masumi Tsuda, Shinya Tanaka, Minoru Tobiume, Masahiro Asaka, and Yusuke Ohba
See commentary p. 3822
- 3976 **Genetically Abnormal Circulating Cells in Lung Cancer Patients: An Antigen-Independent Fluorescence *In situ* Hybridization-Based Case-Control Study**
Ruth L. Katz, Weigong He, Abha Khanna, Ricardo L. Fernandez, Tanweer M. Zaidi, Matthew Krebs, Nancy P. Caraway, Hua-Zhong Zhang, Feng Jiang, Margaret R. Spitz, David P. Blowers, Carlos A. Jimenez, Reza J. Mehran, Stephen G. Swisher, Jack A. Roth, Jeffrey S. Morris, Carol J. Etzel, and Randa El-Zein
- 3988 **BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy**
Charles Dumontet, Maryla Krajewska, Isabelle Treilleux, John R. Mackey, Miguel Martin, Mathieu Rupin, Laurence Lafanechère, and John C. Reed


CANCER THERAPY: CLINICAL

- 3998 **Phase II Trial of Short-Course R-Chop Followed by ⁹⁰Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients**
Pier Luigi Zinzani, Giuseppe Rossi, Silvia Franceschetti, Barbara Botto, Alice Di Rocco, Maria Giuseppina Cabras, Maria Concetta Petti, Vittorio Stefoni, Alessandro Broccoli, Stefano Fanti, Cinzia Pellegrini, Gian Carlo Montini, Letizia Gandolfi, Enrico Derenzini, Lisa Argnani, Mariapaola Fina, Alessandra Tucci, Chiara Bottelli, Stefano Pileri, and Michele Bacarani

- 4005 **Phase I/II Study of Oncolytic HSV^{GM-CSF} in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck**
Kevin J. Harrington, Mohan Hingorani, Mary Anne Tanay, Jennifer Hickey, Shreerang A. Bhide, Peter M. Clarke, Louise C. Renouf, Khin Thway, Amen Sibtain, Iain A. McNeish, Kate L. Newbold, Howard Goldsweig, Robert Coffin, and Christopher M. Nutting
- 4016 **A Single-Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult Subjects**
Bruce Hug, Richat Abbas, Cathie Leister, Jaime Burns, and Daryl Sonnichsen
- 4024 **Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group**
Carola A.S. Arndt, Nadya V. Koshkina, Carrie Y. Inwards, Douglas S. Hawkins, Mark D. Krailo, Doojduen Villaluna, Peter M. Anderson, Allen M. Goorin, Martin L. Blakely, Mark Bernstein, Sharon A. Bell, Kaylee Ray, Darryl C. Grendahl, Neyssa Marina, and Eugenie S. Kleinerman
- 4031 **Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration-Approved Treatment**
Ignacio Garrido-Laguna, Filip Janku, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Joanne Aaron, Xuemei Wang, Merrill Kies, and Razelle Kurzrock
- 4038 **Phase I Dose Finding Studies of Obatoclox (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma**
Jimmy J. Hwang, John Kuruvilla, David Mendelson, Michael J. Pishvaian, J.F. Deeken, Lillian L. Siu, Mark S. Berger, Jean Viallet, and John L. Marshall
- 4046 **A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients**
Nancy J. Nessler, Alvin Ng, Kwong-Yok Tsang, Theresa Ferrara, Jeffrey Schlom, James L. Gulley, and Brad H. Nelson
- 4057 **Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection**
Brian A. Ginsberg, Humilidat F. Gallardo, Teresa S. Rasalan, Matthew Adamow, Zhenyu Mu, Sapna Tandon, Barrett B. Bewkes, Ruth-Ann Roman, Paul B. Chapman, Gary K. Schwartz, Richard D. Carvajal, Katherine S. Panageas, Stephanie L. Terzulli, Alan N. Houghton, Jianda D. Yuan, and Jedd D. Wolchok

ABOUT THE COVER

CXC chemokine receptor 2 (CXCR2) expression in an ovarian cancer cell line detected by the immunofluorescent staining. Overexpression of CXCR2 in ovarian cancer cells leads to dysregulation of cell cycle, decreased apoptosis, and increased angiogenesis. The high level expression of CXCR2 also predicts poor prognosis in patients with high-grade ovarian serous carcinoma. For further details, please see the article by Yang and colleagues on page 3875 of this issue.



Clinical Cancer Research

16 (15)

Clin Cancer Res 2010;16:3809-4065.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/15>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/16/15>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.